clinical trial · NCT06176508
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
Hansoh BioMedical R&D Company·phase2·recruiting·n = 160
Psoriatic ArthritisHS-10374HS-10374-matched placebo tabletsTofacitinib 5Mg Tab,Oral
brief summary
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.
started
Feb 26, 2024
primary completion
Apr 28, 2026
completion
Aug 28, 2026
last updated
Jul 18, 2024
official title
A Randomized, Double-blind, Placebo- and Comparator-controlled, Multicenter, Phase 2 Trial to Assess the Efficacy and Safety of HS-10374 in Adults With Active Psoriatic Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol